Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.99T
24h Vol:
$10.08B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  BSX

Boston Scientific Corp

BSX
71 / 100
S&P500
$66.43arrow_drop_down-0.35%-$0.24

Performance History

Stocklytics logo
Key Stats
Open$67.07
Prev. Close$67.00
EPS1.07
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$97.81B
PE Ratio62.31
LOWHIGH
Day Range66.64
67.32
52 Week Range46.20
67.32
Ratios
P/B Ratio5.10
Revenue$14.24B
Operating M. %16.56%
Earnings$1.59B
Earnings Growth %128.08%
EBITDA Margin %25.37%
ROE %8.58%
EPS1.07

Score Breakdown

71vs 53. Market Avg.

All Score 71 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

BSXMARKET
Value2139
Quality7140
Ownership4119
Growth6746
Dividends-37
check_circle

Boston Scientific Corp's Price growth average in the last 3 years of 20.51% is great compared to market average of 6.47%. This indicates BSX could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$765.00
24H (%)arrow_drop_down-0.89%
24H ($)-$6.91
MARKET CAP$726.87B
PRICE$513.41
24H (%)arrow_drop_down-2.26%
24H ($)-$11.90
MARKET CAP$474.87B
PRICE$160.98
24H (%)arrow_drop_up0.11%
24H ($)$0.19
MARKET CAP$387.76B
PRICE$129.03
24H (%)arrow_drop_up0.14%
24H ($)$0.19
MARKET CAP$326.96B

About Boston Scientific Corp (BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Michael F. Mahoney
Headquarters
Marlborough
Employees
45000
Exchange
NYSE
add Boston Scientific Corp to watchlist

Keep an eye on Boston Scientific Corp

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Boston Scientific Corp's (BSX) price per share?

The current price per share for Boston Scientific Corp (BSX) is $66.43. The stock has seen a price change of -$0.24 recently, indicating a -0.36% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Boston Scientific Corp (BSX)?

For Boston Scientific Corp (BSX), the 52-week high is $67.32, which is 1.34% from the current price. The 52-week low is $46.2, the current price is 43.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Boston Scientific Corp (BSX) a growth stock?

Boston Scientific Corp (BSX) has shown an average price growth of 20.65% over the past three years. It has received a score of 84 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Boston Scientific Corp as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Boston Scientific Corp (BSX) stock price performance year to date (YTD)?

As of the latest data, Boston Scientific Corp (BSX) has a year-to-date price change of 14.87%. Over the past month, the stock has experienced a price change of 8.33%. Over the last three months, the change has been 20.94%. Looking at a longer horizon, the five-year price change stands at 65.58%.

question_mark
Is Boston Scientific Corp (BSX) a profitable company?

Boston Scientific Corp (BSX) has a net income of $1.59B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 69.49% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 16.56% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $14.24B, with a revenue growth rate of 12.29%, providing insight into the company's sales performance and growth. The gross profit is $9.9B. Operating income is noted at $2.34B. Furthermore, the EBITDA is $3.62B.

question_mark
What is the market capitalization of Boston Scientific Corp (BSX)?

Boston Scientific Corp (BSX) has a market capitalization of $97.46B. The average daily trading volume is 5.76M, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.